Educational research on US and Indian equities, ETFs, mutual funds and crypto, with screeners and a free investing academy.
All data is for educational purposes only and should not be considered investment advice.
Equiscale is operated by Syntellia LLC, a Delaware limited liability company.
© 2026 Syntellia LLC. All rights reserved.
KalVista Pharmaceuticals, Inc., a biopharmaceutical company, develops oral therapies for individuals for rare diseases with unmet needs. Its lead product candidate is EKTERLY, a fast-acting potent inhibitor of plasma kallikrein for the treatment of acute attacks of hereditary angioedema (HAE). The company is also developing is developing an orally disintegrating tablet formulation; KONFIDENT-KID for pediatric use with HAE; KONFIDENT; and KONFIDENT-S to evaluate sebetralstat and ODT formulation in adolescent and adult patients. KalVista Pharmaceuticals, Inc. is headquartered in Framingham, Massachusetts.
5-year financial trends
No historical performance data available.
No growth data available
No growth data available.
Year-by-year revenue, profitability, and cash flow (USD millions, last 0 years)
No historical growth data available.
Income statement, balance sheet, and cash flow as reported
No financial statement data available.
Sector peers ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| KALVthis co. | KALV | - | - | - | - | - |
| INmune Bio Inc. | INMB | $36M | -0.78 | 1.53 | -195.3% | -0.40 |
| Neonode Inc. | NEON | $31M | 3.66 | 1.26 | 34.4% | 0.79 |
| Tvardi Therapeutics, Inc. | TVRD | $29M | -1.59 | 1.38 | -87.0% | -0.31 |
| GoHealth, Inc. | GOCO | $21M | -0.08 | 0.56 | -678.9% |
| -1.98 |
| Sleep Number Corporation | SNBR | $8M | - | - | 22.8% | 105.20 |
| zSpace, Inc. | ZSPC | $1M | -0.04 | -0.04 | 112.8% | -0.75 |
| Trinseo PLC | TSEOF | $0M | -0.00 | -0.00 | 49.7% | 39.40 |
| ACCO Brands Corporation | ACCO | $0M | 0.00 | 0.00 | 6.2% | 5.11 |
| Peer Median | - | -0.04 | 0.56 | 14.5% | 0.24 | |